PHC GROUPPHC Holdings Corporation

  • About Us
  • Group Companies
  • Products & Services
  • Sustainability
  • Investor Relations
  • Newsroom

About Us

About PHC GroupCEO MessageMission, Vision & ValuesValue Creation PlanHistory LeadershipPHC Group by the Numbers

Group Companies

Ascensia LSI Medience Wemex Mediford Epredia PHCbi PHC IVD

Products & Services

Cancer Pathology Biologic & Cell Preservation Diagnostic Testing Patient Record & Billing Software Diabetes Management Medical Device & Drug Delivery

Sustainability

Sustainability
  • CEO Message
  • Materiality
  • Sustainability Management
  • PHC GROUP Integrated Report
  • Environment image
    Environment
  • Society image
    Social
  • Governance image
    Governance

Investor Relations

INVESTOR RELATIONS

MANAGEMENT

  • Corporate Governance
  • IR Basic Policy
  • Business Risks

IR LIBRARY

  • Financial Results
  • Presentation Materials
  • IR Materials
  • Historical Financial Data
  • PHC GROUP Integrated Report
  • Mid-term Plan
  • Our Group Introduction

STOCK INFORMATION

  • Stock Overview
  • General Meeting of Shareholders
  • Shareholder Newsletter
  • Stock Quotations
  • Analyst Coverage
IR News Financial Highlights IR Calendar Contact IR Disclaimer

Newsroom

NEWSROOM

NEWS

  • PHC Holdings Corporation
  • PHC Group Companies
CareersContact
JP

Other PHC Group Websites

  • Ascensia Diabetes Care Holdings AG
  • PHC Corporation
  • LSI Medience Corporation
  • Wemex Corporation
  • Mediford Corporation
  • Epredia Holdings Ltd.
  • PT PHC Indonesia
  • PHC Corporation of North America
  • PHC Europe B.V.
  • SciMed (ASIA) Pte Ltd
  • Amelieff Corporation

Other PHC Group Websites

  • Ascensia Diabetes Care Holdings AG
  • PHC Corporation
  • LSI Medience Corporation
  • Wemex Corporation
  • Mediford Corporation
  • Epredia Holdings Ltd.
  • PT PHC Indonesia
  • PHC Corporation of North America
  • PHC Europe B.V.
  • SciMed (ASIA) Pte Ltd
  • Amelieff Corporation
CareersContactJP
Newsroom > 2022 > Announcement of Resignation and Change in Role of Corporate Officer at PHC Holdings Corporation

News


2022

NewsDecember 2

Announcement of Resignation and Change in Role of Corporate Officer at PHC Holdings Corporation

Please be advised that the following changes will take place at PHC Holdings Corporation (headquarters: Minato-ku, Tokyo) and PHC Group Subsidiary.

1. Resignation of Corporate Officer on December 31, 2022

Position/Title Name Role and Responsibilities
Corporate Officer Kyoji Morimoto Technology/Manufacturing
President, Member of Board, PHC Corporation

2. Change in role at PHC Group Subsidiary on January 1, 2023

Position/Title Name Until Dec. 31, 2022 From Jan. 1, 2023
Corporate Officer Nobuaki Nakamura Co-head of Diagnostics & Life Sciences Domain
Director, Member of Board
Biomedical Division, PHC Corporation
Co-head of Diagnostics & Life Sciences Domain
President, Member of Board
PHC Corporation
Biomedical Division

3. Corporate Officers at PHC Holdings Corporation on January 1, 2023

Position/Title Name Role and Responsibilities
Chief Executive Officer (CEO) Shoji Miyazaki Group Management, Internal Audit
Chief Operating Officer (COO) Koichiro Sato Business Domains, Technology,
Manufacturing, Procurement, Risk Management
Senior Executive Corporate Officer
Chief Administrative Officer (CAO)
Chief Human Resources Officer (CHRO)
Chief Transformation Officer (CTO)
Ryuichi Hirashima General Affairs, Human Resources, Legal & Compliance, Intellectual Property, Transformation
Executive Corporate Officer
Chief Financial Officer (CFO)
Frederick Reidenbach Corporate Accounting, Corporate Finance,
Information Technology
Executive Corporate Officer
Chief Strategy Officer (CSO)
Kaiju Yamaguchi Corporate Strategy,
Business Development, Investor Relations, Corporate Communications, Medical Policy & Public Affairs
Corporate Officer Robert Schumm Head of Diabetes Management Domain
President,
Ascensia Diabetes Care Holdings AG
Corporate Officer Nobuaki Nakamura Co-head of Diagnostics & Life Sciences Domain
President, Member of Board
Biomedical Division, PHC Corporation
Corporate Officer Takayuki Otsuka Co-head of Healthcare Solutions Domain
Director, Member of Board
Medical Information Systems Division,
PHC Corporation
Corporate Officer Haruo Watanabe Co-head of Healthcare Solutions Domain
President and Chief Executive Officer,
LSI Medience Corporation
Corporate Officer Steven Lynum Co-head of Diagnostics & Life Sciences Domain
President, Epredia Holdings Ltd.

Media contact

Investor Relations & Corporate Communications Department
PHC Holdings Corporation
+81-3-6778-5311
E-mail: phc-pr@gg.phchd.com

  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
Terms of UsePrivacy PolicyFacebookLinkedIn © PHC Holdings Corporation All rights reserved.